Roche’s PiaSky Receives the CHMP’s Positive Opinion for TreatingParoxysmal Nocturnal Haemoglobinuria (PNH)
Shots:
- The CHMP’s positive opinion of PiaSky for PNH adults & adolescents (≥12yrs., 40kg) was based on 3 P-III trials incl. COMMODORE 2 study of PiaSky (SC, Q4W) vs eculizumab (IV, Q2W) in patients not treated with C5 inhibitor; COMMODORE 1 study in subjects switched from C5 inhibitor & COMMODORE 3 study in Chinese subjects new to C5 inhibitor
- COMMODORE 2 study showed that the drug was superior, well-tolerated & attained disease control with 78% vs 80% AEs
- PiaSky (C5 protein inhibiting mAb) is currently being studied under 5 P-III clinical evaluations & 3 earlier phase studies to treat complement-mediated diseases such as PNH, atypical haemolytic uremic syndrome & sickle cell disease
Ref: Roche | Image: Roche
Related News:- Roche’s Ocrevus SC (Ocrelizumab) Receives the EC’s Approval to Treat Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.